Subsequent research has shown that the overexpression of HE4 not only exists in patients with ovarian cancer, but has also been observed in patients with transitional cell carcinoma, lung adenocarcinoma, breast cancer, pancreatic cancer, endometrial carcinoma and so on [22, 23]. Here, WFDC2 is linked to ovarian carcinoma.